Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DA060462 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs (SSPs) to implement routine, opt-out HIV and Hepatitis C (HCV) testing and linkage to care for people who inject drugs (PWID).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ACCESS Group | Experimental | Participants in this group will receive the ACCESS intervention for up to 18 months |
|
| Control Group | Active Comparator | Participants in this group will receive a link to the CDC Compendium of Evidence-Based Interventions for up to 18 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ACCESS Intervention | Behavioral | Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of SSP participants reached | Number of total HIV/HCV tests completed divided by the number of unique individuals seen | up to 18 months |
| Adoption | Proportion of SSPs that have created an HIV/HCV opt-out testing policy | up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of SSP participants reached after the intervention | Number of total HIV/HCV tests completed divided by the number of unique individuals seen | up to 30 months |
Not provided
Inclusion Criteria:
SSPs must:
Exclusion Criteria:
SSPs must not:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hansel Tookes, MD | Contact | 3056897030 | hetookes@miami.edu |
| Name | Affiliation | Role |
|---|---|---|
| Tyler Bartholomew, PhD | University of Miami | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Miami | Recruiting | Miami | Florida | 33136 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Control Group | Behavioral | Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention. |
|
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D008722 | Methods |